Collaboration

#Collaboration #Cystic fibrosis #Neuropsychiatric disorders #RNA #Therapeutics

New episode of the DDW Highlights podcast

The latest episode of the DDW Highlights podcast is now available for download. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  This round-up was compiled by DDW’s Diana Spencer and reflects… Read More

#News

#Collaboration #CRISPR #CRISPR-Cas9 #Cystic fibrosis #Finance #Gene editing #Liver disease #Neuropsychiatric disorders #Oncology #RNA

This week in drug discovery (10-14 October)

News round-up for 10-14 October by DDW Digital Content Editor Diana Spencer The top news in the world of drug discovery this week reflects the vital importance of collaboration, partnership and support within this industry.  Partnerships… Read More

#News

Cancer research in lab
#Cancer research #Collaboration #Genomics #Oncology

Strategic collaboration to enhance targeted oncology programmes

Oncology platform company Tavros Therapeutics and biopharmaceutical company Vividion Therapeutics (a subsidiary of Bayer AG) have agreed to collaborate on four oncology targets across an initial five-year term. Tavros’ functional and computational genomics technologies are designed to uncover unique vulnerabilities within tumours to discover novel targets and biomarkers in areas… Read More

#Business & Investment #Cancer Research #News

#AI #Biopharmaceuticals #Collaboration #Neuroscience #Psychiatry #Therapeutics

Collaboration extended in severe neuropsychiatric disorders 

Clinical-stage biopharmaceutical company Karuna Therapeutics has extended its drug discovery collaboration with PsychoGenics, AI-enabled phenotypic drug discovery and preclinical CRO services.  The collaboration aims to identify potential novel drug candidates for the treatment of severe neuropsychiatric disorders.  The initial multi-year agreement, announced in July 2020,… Read More

#News

Spinal injury
#Collaboration #Orphan drugs #Partnership #Spinal cord injury

Partnership hopes to revolutionise treatment of spinal cord injuries

Terebellum and NeurosolvTherapeutics will partner to launch Perineline, a new patented two-part therapy for spinal cord injuries.  The drug has attained EMA Orphan Designation and it is hoped that it will revolutionise the therapeutic treatment and resulting end patient outcomes from spinal cord injuries.   Terebellum will contribute strategic guidance in… Read More

#Business & Investment #News

#AI #Biotechnology #Collaboration #Drug discovery #Pfizer

Pfizer and CytoReason collaborate to bolster AI in drug discovery

Pfizer has extended its multi-year partnership with CytoReason to use CytoReason’s artificial intelligence (AI) technology for Pfizer’s drug development programs.   Pfizer will make a $20 million equity investment, have options to license CytoReason’s platform and disease models, and fund supplementary project support. This deal which has the potential to be worth up… Read More

#Business & Investment #News

#Alzheimer's #Collaboration #Neurology #US

Cerevance teams up with Merck (MSD) on Alzheimer’s project  

Drug discovery and development company Cerevance has announced a multi-year strategic research collaboration with Merck (MSD), focused on identifying novel targets for Alzheimer’s disease.   Cerevance will receive an upfront payment of $25 million from Merck (MSD) and could receive development and commercial milestone payments of up to… Read More

#News

#Collaboration #Immunology #Oncology

Amphista Therapeutics signs on drug development projects  

Amphista Therapeutics, a company focused on the development of next generation targeted protein degradation (TPD) therapeutics, has signed a strategic collaboration and license agreement with Bristol Myers Squibb.   The companies will work together to discover and develop small molecule protein degraders. Bristol Myers Squibb will be granted a global… Read More

#News

#AI / data analytics / healthtech / informatics #Collaboration

Collaborators leverage AI to enable improved pivotal clinical trials 

Unlearn has entered into a multi-year collaboration with Merck to accelerate late-stage clinical trials with novel trial designs that include Digital Twins. Initially, the collaboration will focus on advancing the regulatory approval of candidates in Merck’s immunology pipeline, with the potential to expand into other therapeutic areas. … Read More

#News

#Collaboration #Infectious diseases #Public health

European Clinical Research Alliance for Infectious Diseases created 

In January 2022, European Clinical Research Alliance for Infectious Diseases (Ecraid) became a legal entity and is now fully operational to advance knowledge in the field of infectious diseases. This is Ecraid’s initial step as it evolves into a self-sustaining, not-for-profit organisation conducting clinical research for both public and… Read More

#News

#AI / data analytics / healthtech / informatics #Biotechnology #Collaboration

This week in drug discovery (21-25 February) 

News round-up by DDW’s Megan Thomas for 21-25 February, 2022  This week’s drug discovery news reflects breakthroughs across therapeutic areas with a focus on collaboration not just between scientists and institutions, but also businesses and regulatory organisations. 1. New human beta cell model enables discoveries in… Read More

#News

#AI / data analytics / healthtech / informatics #Collaboration #Irritable Bowel Syndrome

Can an AI-driven data sharing effort advance IBD treatments? 

Iterative Scopes, provider of precision medicine technologies for gastroenterology, has entered into a data sharing agreement with Pfizer to accelerate the development of potential new treatments for patients suffering from IBD by standardising endoscopic interpretation.  Context  Currently, disease severity scoring systems, such as the Mayo Endoscopic… Read More

#News

#Collaboration #Immunology

Scientists uncover unique immune cell surveillance mechanism 

Researchers at the Francis Crick Institute and King’s College London have identified how specialist immune cells, called gamma delta T cells (γδ T cells), sense the body’s status quo, enabling them to assess the health of surface tissues and even protect against cancer-causing DNA damage.  Context … Read More

#News

#AI / data analytics / healthtech / informatics #Collaboration

Collaboration identifies antibody drug candidates using AI  

Antiverse has partnered with a top 20 pharma company and has been successful in identifying antibody candidates for a target of interest, with greater diversity (2.3x) and accuracy compared to alternative bioinformatics pipeline selection methods.  The sequencing  Using Antiverse’s AI-Augmented Drug Discovery platform, 248 sequences… Read More

#News

#Approvals #Collaboration #Drug discovery #Public health #Research study

This week in drug discovery (14-18 February) 

News round-up by DDW’s Megan Thomas for 14-18 February, 2022  This week, DDW rounds up updates, approvals, research and trials which will enable scientists to make life-saving developments in the drug discovery industry.  1. Trial launched of HIV vaccine antigens delivered through mRNA technology… Read More

#News

#Collaboration #Drug therapy #Neuroscience #Parkinson's

Collaboration targeting neuroinflammation to slow Parkinson’s  

Parkinson’s UK and Domainex have collaborated to develop small molecule therapies targeting neuroinflammation that could slow the progression of Parkinson’s Disease.   Context  Inflammation is vital for defending the body from infections, injuries and toxins. However, in Parkinson’s there is excessive chronic inflammation within the brain. Read More

#News